ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.
ORIC-944 (30, 100, 200 mg/kg; op; everyday for 50 days) induces significantly tumor regressions at all dose levels tested[3].ORIC-944 (30 mg/kg; op; everyday for 30 days) demonstrates strong single agent activity to enzalutamide in prostate cancer xenograft model[3].
References:
[1]. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 6586-6586. [2]. ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones [3]. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models[C]//Cancer Research. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2021, 81(13).